Gastric Cancer, Peritoneal Carcinomatosis
Conditions
Keywords
Peritoneal, Carcinomatosis, Gastric, Cancer, NIPS, HIPEC
Brief summary
Implementation of a curative strategy of treatment in peritoneal carcinomatosis of gastric cancer. The goal is to get 1C level of evidence (patient died with standard treatment, with this treatment some of them survive) in terms of disease free survival and overall survival. Methodology: prospective, phase II, multicentric in Spain. Recruitment of 50 patients(to have 31 on treatment) in three years. This strategy is based on neoadjuvant systemic plus simultaneous intraperitoneal and intravenous chemotherapy(NIPS),to treat peritoneal disease by bi-directional approach; next step is cytoreductive surgery and HIPEC. Once patients are discharged, they will follow a systemic adjuvant chemotherapy protocol.
Detailed description
Patients with peritoneal carcinomatosis with gastric cancer who meet all inclusion criteria(and none of exclusion) will follow the next treatment scheme(40 week period of treatment): Phase I (after one week of peritoneal catheter implant; total treatment 5-8 weeks): intraperitoneal infusion of Docetaxel(30 mg/m2) and Cisplatin (30mg/m2) in 1000 cc of saline. Intravenous administration 5-FU (200 mg/m2/Day, 7 days a week for 2 weeks) simultaneously with 2 cycles of Intraperitoneal administration. These patients receive between four and six cycles of NIPS. Until phase II 4-6 weeks. Phase II:cytoreduction (CR) plus HIPEC (total treatment 4 weeks). Maximal efforts to optimum cytoreduction. HIPEC: intraperitoneal administration: Mytomicin C (15mg/m2)plus Adriamycin (15mg/m2) at 42-43ºC for 60 minutes. Intravenous simultaneously administration 5-FU (400mg/m2) plus Leucovorin (20mg/m2) for 10 minutes at the beginning of peritoneal perfusion. Phase III: adjuvant chemotherapy 8-12 weeks after surgery. Those cases reaching optimum cytoreduction (CC0) will be treated with systemic chemotherapy: First day: Docetaxel (75 mg/m2) Cisplatin (75mg/m2). Days 1-5: 5-FU (750mg/m2/d).
Interventions
OTHERIntraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC
see Design
Sponsors
Instituto de Salud Carlos III
Hospital General Universitario Gregorio Marañon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Men and women aged 18-65 years old * Histological Evidence of peritoneal carcinomatosis from gastric cancer * No distance metastasis * ECOG 0-1-2 * No contraindication for complex surgery * no other malign disease except skin cancer (different from melanoma or cervix cancer CIN III) * willing to consent and sign ICF.
Exclusion criteria
* No Histological Evidence of peritoneal carcinomatosis from gastric cancer * Previous Gastrectomy due to gastric cancer. * Patients with gastric cancer and previous systemic chemotherapy * Peritoneal recurrence due to gastric cancer. * Distance metastasis * SP \>2 at recruitment or SP\>1 at surgery * previous radiotherapy treatment * pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease free survival | 36 months | patients who reached optimum cytoreduction (CC0)after Phase II and eligible to complete adjuvant treatment(Phase III). |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival | 36 months |
| overall survival in patients with CC0 | 36 month |
| overall survival in patients who did not reach optimum cytoreduction | 36 months |
| morbidity and mortality | first 30 days after surgery procedure |
| Quality of life after phase I and Phase II | 36 months |
Countries
Spain
Outcome results
None listed